Text or call a human:Text (808) 600-9260Call
CorporateVentureCapital.com

Sarepta Therapeutics

Profile and portfolio

Parent Sarepta TherapeuticsHQ Cambridge, United States

This profile covers the startup investments made by Sarepta Therapeutics, a pharmaceutical and biotech company. It is based in Cambridge, United States. It invests at the Series A stage. Sectors it names: biotech and life sciences.

Every figure links to its source

Snapshot

Investment stage: Series A to Series A
Data behind this graphic
Data behind this graphic
ItemValue
Stage rangeSeries A to Series A
SectorsBiotech and life sciences
GeographyNorth America
OfficesCambridge, United States

Sources: S1 GlobeNewswire: LEXEO Therapeutics announces strategic investment from Sarepta (28 Aug 2023).

Graphic 1 of 1

Investment stage: Series A to Series A

Sources: S1 GlobeNewswire: LEXEO Therapeutics announces strategic investment from Sarepta (28 Aug 2023).

Download:Report a correction

Where it invests

Geography

Headquarters
Cambridge, United States
Offices
  • Cambridge, United States

Investment regionsS1

Key facts

FactValueStatusSource
Parent companySarepta Therapeutics (NASDAQ: SRPT)Single sourceS1
Parent industryPharmaceuticals and biotechSingle sourceS1
HeadquartersCambridge, United StatesSingle sourceS4
Capital sourceParent company onlySingle sourceS1
StagesSeries A (inferred from announced rounds)EstimateS1

About Sarepta Therapeutics

ItemDetailSource
Listed asNASDAQ: SRPTS1
HeadquartersUnited StatesS1

History

  1. Strategic investment, amount undisclosed (28 August)S1
  2. USD 325M equity purchase of 11.93M shares with collaboration; partly sold in August 2025S3

Portfolio

Public sources name 3 portfolio companies.S1

Every company on the Sarepta Therapeutics list

3 companies, as named in the sources cited.S1 Read the firm's list.

  • Arrowhead Pharmaceuticals
  • LEXEO Therapeutics
  • StrideBio

Official pages

Read the firm's own pages for current information.

Sources

  1. S1GlobeNewswire: LEXEO Therapeutics announces strategic investment from Sarepta (28 Aug 2023)Press
  2. S2Sarepta IR: Sarepta and StrideBio multi-target collaborationFirm
  3. S3Sarepta IR: advancement of siRNA collaboration and sale of Arrowhead equityFirm
  4. S4SEC EDGAR submissions: Sarepta Therapeutics business addressFiling

Disclaimer and corrections

Not affiliated. This page is not affiliated with, endorsed by or sponsored by Sarepta Therapeutics or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.

Spotted a mistake? Report a correction.